Projects per year
Tuberculosis remains a major public health burden. With the emergence of multi-drug resistant strains of Mycobacterium tuberculosis and the sustained HIV epidemic worldwide, the threat of tuberculous infection can be expected to continue for quite some time. Clearly, effective ant-ituberculosis intervention is urgently needed. The goal of this Program Project is to design safe and efficacious anti-tuberculous vaccines. For such an endeavor, animal experimentation designed to evaluate vaccine safeness and efficacy is indispensable. The goal of Core B is to provide the investigators participating in this Program Project with the infrastructure to carry out animal studies. Specifically, Core B will i) maintain a safe, efficient, and up-to-date biosafey-level 3 containment animal facility;ii) provide assistance in the design of animal experiemnts, in data interpretation, and in the technical aspects of the various aerogenic models of murine experimental tuberculosis;iii) maintenance and breeding of specific transgenic and gene-disrupted mice. We believe a central core facility for animal studies will fulfill important goals of a Program Project: i) to enhance efficiency, cost-effectiveness, and productivity of the individual participating laboratories, and ii)to foster interaction and collaboration among the investigators.
|Effective start/end date
|10/1/04 → 3/31/10
- National Institute of Allergy and Infectious Diseases: $181,653.00
- National Institute of Allergy and Infectious Diseases: $184,045.00
- National Institute of Allergy and Infectious Diseases: $142,089.00
- National Institute of Allergy and Infectious Diseases: $204,093.00
- National Institute of Allergy and Infectious Diseases: $190,742.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
- 1 Finished
7/1/05 → 6/30/17
Project: Research project